Total Payments
$31,151
2024 Payments
$2,068
Companies
7
Transactions
36
Medicare Patients
231
Medicare Billing
$46,488
Payment Breakdown by Category
Other$15,000 (48.2%)
Consulting$10,600 (34.0%)
Research$3,518 (11.3%)
Travel$1,243 (4.0%)
Food & Beverage$790.80 (2.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,000 | 10 | 48.2% |
| Consulting Fee | $10,600 | 8 | 34.0% |
| Unspecified | $3,518 | 2 | 11.3% |
| Travel and Lodging | $1,243 | 3 | 4.0% |
| Food and Beverage | $790.80 | 13 | 2.5% |
Payments by Type
General
$27,634
34 transactions
Research
$3,518
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| F. Hoffmann-La Roche AG | $17,067 | 11 | $0 (2024) |
| ROCHE MOLECULAR SYSTEMS, INC. | $6,600 | 7 | $0 (2021) |
| Genentech, Inc. | $5,539 | 8 | $0 (2018) |
| NOVARTIS PHARMACEUTICALS CORPORATION | $1,450 | 1 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $391.70 | 7 | $0 (2019) |
| Hoffmann-La Roche Limited | $54.72 | 1 | $0 (2018) |
| Gilead Sciences Inc | $48.70 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,068 | 1 | F. Hoffmann-La Roche AG ($2,068) |
| 2021 | $3,000 | 5 | ROCHE MOLECULAR SYSTEMS, INC. ($3,000) |
| 2020 | $3,600 | 2 | Roche Molecular Systems, Inc. ($3,600) |
| 2019 | $2,976 | 2 | F. Hoffmann-La Roche AG ($2,965) |
| 2018 | $12,358 | 13 | Genentech, Inc. ($5,407) |
| 2017 | $7,150 | 13 | F. Hoffmann-La Roche AG ($6,774) |
All Payment Transactions
36 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $2,067.56 | Research |
| Study: AN OPEN-LABEL, MULTI-CENTER, DOSE-ESCALATION PHASE I STUDY, TO EVALUATE SAFETY, PHARMACOKINETICS AND THERAPEUTIC ACTIVITY OF RO6958688, A NOVEL T CELL BISPECIFIC ANTIBODY (TCB) TARGETING THE HUMAN CARCINOEMBRYONIC ANTIGEN (CEA) ON TUMOR CELLS AND CD3 ON T CELLS, ADMINISTERED INTRAVENOUSLY, IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC CEA(+) SOLID TUMORS. | ||||||
| 11/24/2021 | ROCHE MOLECULAR SYSTEMS, INC. | — | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| 09/13/2021 | ROCHE MOLECULAR SYSTEMS, INC. | — | Consulting Fee | Cash or cash equivalent | $200.00 | General |
| 08/06/2021 | ROCHE MOLECULAR SYSTEMS, INC. | — | Consulting Fee | Cash or cash equivalent | $200.00 | General |
| 05/27/2021 | ROCHE MOLECULAR SYSTEMS, INC. | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 04/01/2021 | ROCHE MOLECULAR SYSTEMS, INC. | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 12/16/2020 | Roche Molecular Systems, Inc. | DIAGNOSTICS INFORMATION SYSTEMS (Device) | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: Molecular Diagnostics | ||||||
| 09/24/2020 | Roche Molecular Systems, Inc. | DIAGNOSTICS INFORMATION SYSTEMS (Device) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: Molecular Diagnostics | ||||||
| 10/15/2019 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $11.07 | General |
| 06/30/2019 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $2,965.22 | General |
| Category: BioOncology | ||||||
| 09/30/2018 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $1,791.96 | General |
| Category: BioOncology | ||||||
| 06/27/2018 | NOVARTIS PHARMACEUTICALS CORPORATION | KISQALI (Drug) | — | In-kind items and services | $1,450.00 | Research |
| Study: RESEARCH RELATED PUBLICATION SUPPORT • Category: ONCOLOGY | ||||||
| 06/01/2018 | Hoffmann-La Roche Limited | Non-Covered Product (Drug) | Food and Beverage | In-kind items and services | $54.72 | General |
| Category: None | ||||||
| 05/31/2018 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $75.00 | General |
| Category: Oncology | ||||||
| 05/31/2018 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $70.00 | General |
| Category: Oncology | ||||||
| 05/31/2018 | AstraZeneca Pharmaceuticals LP | IMFINZI (Drug) | Food and Beverage | In-kind items and services | $40.00 | General |
| Category: Oncology | ||||||
| 04/27/2018 | Genentech, Inc. | — | Food and Beverage | In-kind items and services | $98.55 | General |
| 04/26/2018 | Genentech, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| 04/26/2018 | Genentech, Inc. | — | Travel and Lodging | Cash or cash equivalent | $551.90 | General |
| 04/26/2018 | Genentech, Inc. | — | Travel and Lodging | In-kind items and services | $366.38 | General |
| 04/26/2018 | Genentech, Inc. | — | Travel and Lodging | In-kind items and services | $325.08 | General |
| 04/26/2018 | Genentech, Inc. | — | Food and Beverage | Cash or cash equivalent | $64.95 | General |
| 03/31/2018 | F. Hoffmann-La Roche AG | TECENTRIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $3,468.97 | General |
| Category: BioOncology | ||||||
| 09/30/2017 | F. Hoffmann-La Roche AG | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $711.65 | General |
| 09/30/2017 | F. Hoffmann-La Roche AG | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $672.21 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AN OPEN-LABEL, MULTI-CENTER, DOSE-ESCALATION PHASE I STUDY, TO EVALUATE SAFETY, PHARMACOKINETICS AND THERAPEUTIC ACTIVITY OF RO6958688, A NOVEL T CELL BISPECIFIC ANTIBODY (TCB) TARGETING THE HUMAN CARCINOEMBRYONIC ANTIGEN (CEA) ON TUMOR CELLS AND CD3 ON T CELLS, ADMINISTERED INTRAVENOUSLY, IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC CEA(+) SOLID TUMORS. | F. Hoffmann-La Roche AG | $2,068 | 1 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,450 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2022 | 4 | 77 | 204 | $77,325 | $19,020 |
| 2021 | 4 | 89 | 236 | $77,980 | $19,404 |
| 2020 | 4 | 65 | 140 | $38,060 | $8,064 |
Total Patients
231
Total Services
580
Medicare Billing
$46,488
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 20 | 85 | $42,075 | $10,499 | 25.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 20 | 82 | $20,500 | $4,942 | 24.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 25 | 25 | $11,750 | $2,844 | 24.2% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 12 | 12 | $3,000 | $734.60 | 24.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 33 | 134 | $33,500 | $8,190 | 24.4% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 18 | 64 | $31,680 | $8,059 | 25.4% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 15 | 15 | $7,050 | $1,735 | 24.6% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 23 | 23 | $5,750 | $1,420 | 24.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 17 | 47 | $11,750 | $2,909 | 24.8% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 13 | 32 | $12,000 | $2,083 | 17.4% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 24 | 45 | $6,300 | $1,540 | 24.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 11 | 16 | $8,010 | $1,532 | 19.1% |
About Dr. Joseph Eder, M.D
Dr. Joseph Eder, M.D is a Hematology & Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1043233497.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joseph Eder, M.D has received a total of $31,151 in payments from pharmaceutical and medical device companies, with $2,068 received in 2024. These payments were reported across 36 transactions from 7 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($15,000).
As a Medicare-enrolled provider, Eder has provided services to 231 Medicare beneficiaries, totaling 580 services with total Medicare billing of $46,488. Data is available for 3 years (2020–2022), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Boston, MA
- Active Since 07/26/2006
- Last Updated 07/08/2007
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1043233497
Products in Payments
- TECENTRIQ (Biological) $13,043
- DIAGNOSTICS INFORMATION SYSTEMS (Device) $3,600
- KISQALI (Drug) $1,450
- IMFINZI (Drug) $185.00
- Non-Covered Product (Drug) $120.81
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Boston
Dr. Julio Hajdenberg, Md, MD
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Dr. Eric Jacobsen, Md, MD
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
Paul Richardson, Md, MD
Hematology & Oncology — Payments: $920,265
Hematology & Oncology $920,265
Matthew Davids, M.d, M.D
Hematology & Oncology — Payments: $808,362
Hematology & Oncology $808,362
David Avigan, M.d, M.D
Hematology & Oncology — Payments: $679,225
Hematology & Oncology $679,225
Anthony Letai, Md, MD
Hematology & Oncology — Payments: $569,795
Hematology & Oncology $569,795